文献速递消化道肿瘤与早癌消化内镜

巴雷特食管进展为高级别异型增生或腺癌前的突变检测

Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
PubMed 文献 · Gastroenterology · 2018-03-31

该回顾性病例对照研究对24例后来进展为高级别异型增生或食管腺癌的巴雷特食管患者与73例至少5年内镜监测未进展者进行比较,发现进展者样本中TP53突变检出率为46%,非进展者为5%,TP53突变与进展风险升高相关(校正风险增加13.8倍,95%CI 3.2-61.0,P<.001),且这些突变常出现在异型增生或拷贝数明显改变之前。

要点

  • 进展者巴雷特食管组织中TP53突变检出率为46%,非进展者为5%。
  • TP53突变使进展校正风险增加13.8倍(95%CI 3.2-61.0,P<.001)。
  • 进展者平均致病突变数为2.5个,高于非进展者的1.2个(P<.001)。

核心结论

  • 在后续进展为高级别异型增生或食管腺癌的患者巴雷特食管组织中,TP53突变数量显著高于未进展者,且这些突变常在异型增生或拷贝数明显改变之前被检出。

研究设计与样本

  • 回顾性病例对照研究,纳入24例进展为高级别异型增生(n=14)或食管腺癌(n=10)的巴雷特食管患者,对照组为73例至少5年内镜活检监测未进展者。
  • 每例患者选取一份组织样本:病例组为进展前1年以上的样本,对照组为随访结束前2年以上的样本。

主要发现

  • 进展者样本中TP53突变检出率为46%,非进展者为5%。
  • 在该病例对照样本集中,巴雷特食管组织TP53突变使进展校正风险增加13.8倍(95%CI 3.2-61.0,P<.001)。
  • 两组间倍性或拷贝数谱未见显著差异。
  • 在57个不同基因中鉴定出147个致病突变,进展者平均致病突变数为2.5个,高于非进展者的1.2个(P<.001)。
  • TP53及其他体细胞突变在拷贝数改变(非整倍体)有限的样本中被反复检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Barrett's esophagus (BE) is the greatest risk factor for esophageal adenocarcinoma (EAC), but only a small proportion of patients with BE develop cancer. Biomarkers might be able to identify patients at highest risk of progression. We investigated genomic differences in surveillance biopsies collected from patients whose BE subsequently progressed compared to patients whose disease did not progress. METHODS: We performed a retrospective case-control study of 24 patients with BE that progressed to high-grade dysplasia (HGD, n = 14) or EAC (n = 10). The control group (n = 73, called non-progressors) comprised patients with BE and at least 5 years of total endoscopic biopsy surveillance without progression to HGD or EAC. From each patient, we selected a single tissue sample obtained more than 1 year before progression (cases) or more than 2 years before the end of follow-up (controls). Pathogenic mutations, gene copy numbers, and ploidy were compared between samples from progressors and non-progressors. RESULTS: TP53 mutations were detected in 46% of samples from progressors and 5% of non-progressors. In this case-control sample set, TP53 mutations in BE tissues increased the adjusted risk of progression 13.8-fold (95% confidence interval, 3.2-61.0) (P < .001). We did not observe significant differences in ploidy or copy-number profile between groups. We identified 147 pathogenic mutations in 57 distinct genes-the average number of pathogenic mutations was higher in samples from progressors (n = 2.5) than non-progressors (n = 1.2) (P < .001). TP53 and other somatic mutations were recurrently detected in samples with limited copy-number changes (aneuploidy). CONCLUSIONS: In genomic analyses of BE tissues from patients with or without later progression to HGD or EAC, we found significantly higher numbers of TP53 mutations in BE from patients with subsequent progression. These mutations were frequently detected before the onset of dysplasia or substantial changes in copy number.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Stachler MD, Camarda ND, Deitrick C, et al. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology. 2018. PMID: 29608884. doi:10.1053/j.gastro.2018.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。